Monte Rosa Therapeutics, Inc.
GLUEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMonte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively. The company carries a $924.8M market cap, placing it firmly in the small-cap category. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Market Cap
$924.8M
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
-5.87
EPS (TTM)
$-1.75
EPS (Fwd)
$-1.85
ROE
-42.7%
ROA
-21.6%
Cash
$621.1M
Total Debt
$38.0M
Free CF
-$74.4M
52W Change
-12.0%
Annual Financials
Cash vs Debt
Where GLUE stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, GLUE finished 43.37% below its 150-day moving average ($17.20) and 45.50% below its 200-day moving average ($17.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GLUE overbought or oversold?
At the October 19, 2026 close, GLUE's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $621.1M in cash comfortably exceeding the $38.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$74.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, GLUE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing GLUE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.